Show results for
Refine by
Antigen Targeting Suppliers Serving Libya
39 companies found
based inLake Forest Park, WASHINGTON (USA)
IEH was founded in 2001 by Dalia Alfi and Mansour Samadpour, who left their positions at the University of Washington, School of Public Health, to start the company. It is a family-owned and operated company and has grown rapidly since 2001, both ...
Undeclared allergens constitute a large portion of food recalls, and there is a tendency to underestimate the impact of allergens on susceptible populations. We offer a comprehensive array of qualitative and quantitative allergen testing, food ...
based inOxford, UNITED KINGDOM
Blue Earth Diagnostics is an established molecular imaging company on a growth trajectory to provide innovative, well differentiated diagnostics solutions, informing patients and driving future therapies in cancer. Formed in 2014, Blue Earth ...
Therapeutic nuclear medicine, also known as theranostics, combines tumour targeting with a therapeutic dose of radiation. Tumour targeting allows radiopharmaceuticals to selectively target cells ...
based inCambridge, UNITED KINGDOM
Based in Cambridge, one of Europe's largest bioscience hubs, Biorbyt has a simple yet challenging mission: to provide the best service to the global scientific community. We achieve this by collaborating with the world’s finest researchers and ...
Plasma cells are specialised B lymphocytes that secrete antibodies (glycoproteins) in response to infection by antigens (toxins or foreign substances). Antibodies, also known as immunoglobulins (Ig), usually have a high affinity to a specific ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...
based inDallas, TEXAS (USA)
Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many ...
based inSan Francisco, CALIFORNIA (USA)
Icosagen is a research-driven contract research provider for biopharmaceutical and biotechnology industries that deftly adapts to market forces and current trends, and is always guided by the needs of its customers. The Group comprises four ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally designed synthetic agents to ...
based inYuseong-gu, SOUTH KOREA
We strive to become a leading biotech company that contributes to human health and well-being by providing innovative therapeutic antibodies to patients with unmet medical needs. We have been committed to developing novel antibody therapeutics since ...
The dual target antibody platform technology of PharmAbcine is based on the fully human antibody candidates selected from HuPhage biopanning process. Depending on antigen presentation patterns on ...
based inYokohama, JAPAN
MabGenesis Inc. is a biopharmaceutical startup that uses 30+ years of antibody research to provide first-in-class and best-in-class therapeutic monoclonal antibody drugs for humans and animals. We have the world’s highest quality antibody libraries ...
based inGembloux, BELGIUM
Based in Belgium and established in 1996, Coris BioConcept is a middle-sized company (SME) specialized in developing, manufacturing and marketing rapid diagnostic kits for the detection of human respiratory, gastro-enteric and blood-borne pathogens ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer ...
based inRedcar, UNITED KINGDOM
Absolute Antibody was founded in 2012 with a vision to make engineered recombinant antibodies accessible to all, and we remain the only company 100% focused on recombinant antibody technology. Though recombinant antibodies are standard in the ...
Binding multiple epitopes with a single antibody offers several benefits. For example, one specificity may target individual molecules while another could recruit effector cells or deliver a drug to the target. Other options include dual-target ...
based inPipersville, PENNSYLVANIA (USA)
LAMPIRE specializes in custom polyclonal & monoclonal antibody development, secondary antibodies, IgGs, BSA, animal blood, tissues & organs, normal & disease state human serums & plasmas, cell media, OMNI C3 cell culture bags & contract ...
LAMPIRE began providing quality antibody support services in 1977. From antigen design and peptide synthesis to antibody purification, buffy coats (PBMCs), spleenectomies, bone marrow extractions, QC testing and labeling, our expert staff is ...
based inCarlton South, AUSTRALIA
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease ...
CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target ...
based inLondon, UNITED KINGDOM
Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic ...
At TREOS we use knowledgebase and algorithm embedded in PASCal (Personal Antigen Selection Calculator) tool to develop personal cancer immunotherapies. PASCal supports the development of immunotherapies for single individuals and a population of ...
based inÜmraniye, TURKEY
Vitrosens Biotechnology is a high-tech company in Turkey founded for the development, manufacture, and delivery of in vitro diagnostic devices (IVD) to the world. Vitrosens Biotechnology headquartered in Turkey, by a group of entrepreneurs with a ...
Test kit enables the qualitative determination of Rotavirus antigens in human fecal samples. It is an effective tool for the diagnosis of acute gastroenteritis resulting from a rotavirus infection. ...
based inLangenfeld, GERMANY
ARTES Biotechnology is a globally working, well established and reliable technology provider for recombinant protein production. We develop microbial cell lines and processes for vaccines, biopharmaceuticals, biosimilars and enzymes and offer ...
based inMons, BELGIUM
D-tek s.a. is a private Belgian biotechnology company created in 1995 in Mons (40 km from Brussels and less than 1h20 from Paris). The company is located in 1.200 square meters facilities in the Scientific Park Initialis of Mons. The company is ...
The M2 antibodies belong to the group of Anti-Mitochondrial Antibodies (AMA) and are strongly associated with PBC. At least 9 distinct AMA have been identified, which have been classified M1-M9 according to their antigen specificity and disease ...